SCHEMBL21150135

SCHEMBL21150135

COc1cc(C(=O)N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2sccc2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 14/20 0.64
▸ INSR P06213 4/20 0.59
▸ PTK2 Q05397 4/20 0.59
▸ ROS1 P08922 3/20 0.59
▸ IGF1R P08069 3/20 0.59
▸ BMPR1B O00238 2/20 0.59
▸ PLK4 O00444 2/20 0.59
▸ GAK O14976 2/20 0.59
▸ ERN1 O75460 2/20 0.59
▸ STK10 O94804 2/20 0.59
▸ ABL1 P00519 2/20 0.59
▸ EGFR P00533 2/20 0.59
▸ LCK P06239 2/20 0.59
▸ FYN P06241 2/20 0.59
▸ FES P07332 2/20 0.59
▸ YES1 P07947 2/20 0.59
▸ HCK P08631 2/20 0.59
▸ FER P16591 2/20 0.59
▸ EPHA2 P29317 2/20 0.59
▸ LTK P29376 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21150898 0.94 ALK (0.56) ALKINSRPTK2ROS1IGF1R
SCHEMBL21150649 0.89 ALK (0.52) ALKINSRPTK2ROS1IGF1R
SCHEMBL19921103 0.89 ALK (0.78) ALKINSRPTK2ROS1IGF1R
SCHEMBL21150935 0.88 ALK (0.82) ALKINSRPTK2ROS1IGF1R
SCHEMBL21099617 0.87 LRRK2 (0.53) ALKINSRPTK2IGF1REGFR
SCHEMBL3956400 0.86 ALK (0.62) ALKINSRPTK2ROS1IGF1R
SCHEMBL19867188 0.83 ALK (0.82) ALKINSRPTK2ROS1IGF1R
SCHEMBL19867189 0.83 ALK (0.84) ALKINSRPTK2ROS1IGF1R
SCHEMBL19921077 0.82 MAPK7 (0.54) ALKINSRPTK2ROS1IGF1R
SCHEMBL19867326 0.82 ALK (0.52) ALKPTK2LRRK2JAK2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof Hongyun Biotech Co., Ltd. (CN) 2021-08-03 — — US disclosed
US-20200207779-A2 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2020-07-02 — — US disclosed
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF ALK, MET, TIE1 ALK 1/4885INSR 2213/4885PTK2 141/4885
US-20200207779-A2 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF ALK, MET, TIE1 ALK 1/4885INSR 2213/4885PTK2 141/4885
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof ALK, MET, TIE1 ALK 1/4885INSR 2213/4885PTK2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback